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CDH1 germline alterations are notoriously responsible for the development of hereditary diffuse gastric cancer
(HDGC), an inherited autosomal cancer syndrome. Discovered for the first time in New Zealand in three Ma¯ori
kindred, severalCDH1 alterations have also been identified in different ethnic populations to date. These mutations
affect, with high frequency, areas with otherwise low incidence of gastric carcinoma (GC), as well as the Ma¯ori
population. In this brief review, we report and describe the CDH1 germline mutations recognized in this ethnicity.
GC incidence
GC is the fourth most common cancer worldwide, with about 934,000 new cases per year (8.6% of new cases of
tumor per year) as estimated in 2002, after lung, breast and colorectal. GC is the second leading cause of cancer-
related death, with 700,000 deaths annually. The incidence is significantly higher in less developed countries, with
42% represented by China alone. There is a wide variation in the distribution of GC between different areas of
the world: high-risk areas include East Asia (China, Japan and Korea), Eastern Europe and parts of Central and
South America. In Southern Asia, North and East Africa, North America, Australia, New Zealand and Africa the
incidence rates are low (<10 per 100,000 in men) [1].
In Europe, GC is the fifth most common cancer, after colorectal, breast, lung and prostate, with an incidence of
149,000 new cases per year and a mortality rate of 116,000 per year. Eastern Europe is the area with the highest
incidence of GC with 70,000 new cases per year just in the Belarus area [2].
The Ma¯ori ethnic group
The ancestors of the Ma¯ori were indigenous Polynesian people from Southeast Asia. They traveled by sea with
typical canoes to New Zealand between 1250 and 1300 and for many centuries they lived in isolated communities.
Thanks to this condition and due to New Zealand’s distance from other landmasses, they developed peculiar
culture, traditions, language and religion, distinguishing this tribal group from any other.
Nowadays the Ma¯ori ethnicity is a consistent part of New Zealand population; in 2010 it was estimated to be
around the 15% (more or less 660,000 individuals) and the te reo, the Ma¯ori language, is one of the New Zealand’s
official languages since 1987, spoken by about 3.7% of the population.
A higher incidence of GC in Ma¯ori population was recognized in 1964 by Jones [3]. After examining this ethnic
group for 30 years, it was observed that gastric cancer affected and led to death of over 25 family members. The
first family tree under examination was composed of 98 members, 28 (28.6 %) of which developed a primary GC
and two a colon cancer. Contrary to what might be expected, the incidence of different kind of cancers in this
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family was average. Fourteen years-old was the earliest death reported in series, but the majority of deaths occurred
before age of 40.
Among the 28 cases of gastric cancer, the distribution in gender was equivalent: 14 males and 14 females, with a
mean age at diagnosis of respectively 36 and 31 years, showing a lower age of disease onset in females. The overall
mean age at onset was 34 years. These data show a wide difference with general population in New Zealand, in
which about the 80% of GCs occur in people over 60 years of age.
Data about the annual incidence of GC among New Zealand population are available online on the government
website [4]. In this annual report, the population is split into Ma¯ori and non-Ma¯ori and it gives the opportunity to
observe a significant increase in incidence in Ma¯ori of both sexes since 2000, in contrast with incidence rates in the
non-Ma¯ori population which continued to uniformly decline [5].
E-cadherin germline mutations
A pathogenic CDH1mutation is estimated to be present in about 40% of families with HDGC (defined as families
from low-incident populations with two or more cases of gastric cancers with at least one proven DGC diagnosed
in an individual before age 50) [6]. Oliveira et al. [7] indicated that germline CDH1 point or small frameshift
mutations can be found in 30–50% of HDGC families.
The penetrance of HDGC is approximately 70% in CDH1 mutation carriers [6,8].
Women with a mutation in CDH1 and members of HDGC families have a lifetime risk of roughly 40% to
develop a breast lobular carcinoma [9,10].
The CDH1 germline mutation is the sine qua non of getting the diagnosis of HDGC. In 2010, the International
GastricCancer LinkageConsortiumpublished updated recommendations [11] for genetic testing, surgery, endoscopy
and pathology for HDGC with CDH1 mutations. Currently, genetic test criteria consider individuals diagnosed
with DGC before the age of 40 years even if there is no family history. A test should also be performed in families
with diagnoses of both DGC and lobular breast cancer, if at least one person has the onset before the age of 50
years. Testing is considered appropriate from the age of the consent. Before the genetic test, it is required to have
an appropriate counseling and a discussion with the multidisciplinary team. A recognized CDH1 mutation in
women increased the risk of developing a lobular breast cancer (LBC) and an annual mammography and breast
MRI should be performed from the age of 35.
The CDH1 germline mutation carriers with a diagnosis of LBC have a high risk of HDGC syndrome [9]. Vice
versa, an early onset of LBC might be the first presentation of HDGC.
Benusiglio et al. [12] identified CDH1 germline deleterious mutations in three bilateral LBC cases (age at
onset <50 years) not fulfilling the International Gastric Cancer Linkage Consortium criteria.
These families have no history of HDGC in first- and second-degree relatives and no BRCA1 and BRCA2
mutations. In another series reported by Petridis, five CDH1 mutations have been identified in four bilateral early
onset LBCs (age at onset <50 years) with no family history for HDGC [13]. Furthermore, Silva et al. reported
two female patients with LBC (ages 60 and 51), both carriers of germline CDH1 mutations, who underwent
prophylactic gastrectomy that revealed foci of intramucosal DGC in both cases [14].
Very recently, two potentially pathogenic CDH1 alterations were reported in patients with LBC without a
family history of gastric tumor [15,16]. Considering only individuals with LBC and excluding genealogical chart
with gastric tumor occurrence, a total of 495 female LBCs from six independent original studies were screened for
CDH1 genetic alterations. Sixteen (3.2%) novel CDH1 germline variants have been identified. Bilateral LBC was
diagnosed in 14.3% of cases (6/63), positive family history for BC was reported in 40.3% and the mean age at
onset was about 45 years-old [17].
DGC lesions are submucosal and the screening with endoscopy with multiple biopsies are inadequate for early
diagnosis [18]. A possible diagnostic delay and the high mortality rate made the prophylactic total gastrectomy a
viable option for mutation carriers [8,19,20]. The prophylactic surgery should be strongly evaluated in centers of
excellence. As every prophylactic surgery, also the choice of a total gastrectomy may be an extremely problematic
emotional experience [20–22] and a compassionate genetic counseling should be guaranteed.
For the CDH1 pathogenic mutation carriers that refuse the option of a prophylactic surgery, a strictly endoscopic
surveillance at centers of expertise is highly recommended. In the same way also all the patients who have genetical
modification of undetermined significance and all the members of families in which a germline mutation has not
yet been identified should be controlled every year [23].
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In 1998, Guilford et al. first detected three different germline mutations in CDH1 gene in three Ma¯ori families
from New Zealand. In those families with a high incidence of DGC were found a splice site (lO0BG>T), a
frameshift (238 2- 238 6, Cins) and a premature termination (TAG, 2095C>T) germline mutation in the E
cadherin gene [24], respectively.
In 1999, the International Gastric Cancer Linkage Consortium defined this predisposition as HDGC [25].
Other international studies subsequently identified novel CDH1 germline alterations in families Ma¯ori-unrelated.
Notably, the majority of these pathogenic CDH1 germline alterations ‘affect’ some countries otherwise classified
as low risk for GC, as well as New Zealand, with higher frequency [26]. Thus, environmental factors, such as
food consumption and lifestyle habits, have been investigated in association to stomach carcinogenesis and tumor
development in countries with high incidence of GC [27].
In a recent study by Hakkaart et al. [28], 17 CDH1 germline alterations were identified in 94 Ma¯ori individuals
with GC (18%), with 34% of them diagnosed with HDGC, one of the highest frequencies ever reported in
literature.
In details, five pathogenic alterations (three nonsense, one frameshift and one missense) were identified. The
three nonsense mutations (190C>T, 1792C>T and 2287G>T) and one frameshift mutation (2381 2386insC)
were identified in four cases each, while the deleterious missense mutation (2195G>A) was identified in a single
case.
The nonsense and frameshift mutations had already been identified previously in Ma¯ori families in New
Zealand [29]. 2195G>A is a splice siting alteration that creates a new acceptor splice site and a large deletion in
the E-cadherin protein, identified in a family from the UK with HDGC diagnosis [30]. 2195G>A had previously
been detected in two families of northern European origin with HDGC [31]. Finally, 2195G>A was reported for
the first time in New Zealand Ma¯ori population.
Conclusion
The results of CDH1 screening in the Ma¯ori are in marked contrast with findings from other GC patients. In fact,
incidence of CDH1 germline mutations is higher in the Ma¯ori in comparison with other ethnicities. New Zealand
is considered a low-risk GC area and frequency of E-cadherin germline alterations is rather high, while in high
risk GC areas CDH1 germline mutations are rarely identified. It is reasonable to imply that CDH1 pathogenic
germline alterations are strong contributors to the high frequency of HDGC in countries with low incidence of
gastric carcinoma, as well in Ma¯ori population.
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